Warning icon The browser that you are currently trying to use to access the HCAI DCS system is not a compatible browser version.

HCAI DCS system is best viewed in Internet Explorer 9, 10, 11, Firefox, Google Chrome and Microsoft Edge.
Help | AAA
Further Reading
Supplementary Information
CPE PPE Study 2022 – information on PPE and enrolment

Public Health England’s Healthcare Associated Infections and Antimicrobial Resistance department (PHE HCAI & AMR) are planning a point prevalence survey (PPS) into carbapenemase-producing Enterobacterales (CPE) in intensive care. The PPS will run, subject to capacity, in the first two weeks of April 2022. We will select NHS Trusts from across England at random and invite them to participate in one or several age categories of intensive care: adults, paediatrics, and neonates. Units which provide level 3 care, either exclusively or alongside other levels, will be eligible. If selected, each Trust will be asked to randomly sample up to 20 patients from their intensive care units, who are inpatients on a single day (chosen by the Trust) within the two-week study period. Trusts with fewer than 20 occupied ICU beds should include all their current inpatients. The CPE PPS will enable PHE to estimate the prevalence of CPE in intensive care in England, across adult, paediatric, and neonatal populations. It will also allow us to identify key risk factors for CPE colonisation and infection, which will inform preventive measures. You will hear from us in the next week or two if your Trust is randomly selected to participate. We will send further information and the study protocol then. Participation is voluntary but we would be grateful of your support in this important study. If you are not randomly selected, but are keen for your Trust to participate, please do get in touch at cpe.pps@phe.gov.uk we are happy for additional Trusts to be involved.